Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received Health Canada Product License PN 80144141 for its natural health product Qlarity, marking a significant regulatory milestone for the biopharmaceutical company. The license authorization permits the sale of Qlarity in Canada with recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance and fatigue reduction.
The Health Canada approval represents an important expansion of Quantum BioPharma's commercial footprint, building upon the company's previous licensing of a similar product in the United States under the brand name unbuzzd™. This regulatory clearance demonstrates the company's ability to navigate complex health product approval processes across multiple jurisdictions, potentially opening additional international markets for their product portfolio.
Quantum BioPharma maintains a strategic position in the development of treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this research particularly significant for patients suffering from this debilitating condition.
The company's business model includes strategic partnerships and spin-out arrangements, as evidenced by its relationship with Unbuzzd Wellness Inc. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, along with royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its ability to pursue higher-value medical applications.
Additional corporate information is available in the company's newsroom at https://ibn.fm/QNTM. The latest regulatory approval strengthens Quantum BioPharma's position in the competitive biopharmaceutical landscape while providing Canadian consumers with access to scientifically-backed natural health products designed to support cognitive function and metabolic health.
